USA: A cross-sectional analysis of US national survey data found that adults aged 65 years and older with type 2 diabetes (T2D) consumed an average of 0.87 g/kg/day of protein, below the recommended intake of 1.0–1.2 g/kg/day. In contrast, adults aged 20–64 years consumed 0.89 g/kg/day, exceeding the recommended allowance of 0.8 g/kg/day.

Although glucagon-like peptide-1 receptor agonist (GLP-1 RA)
users reported lower protein intake per kilogram than nonusers, the difference was not statistically significant after adjustment. The findings highlight the need to address adequate protein intake in older adults with T2D, particularly to help preserve muscle mass and prevent sarcopenia.
The study, published in Obesity Pillars, was authored by Joshua T. Harvey, MPH, from the Department of Population and Quantitative Health Sciences, University of Massachusetts Chan Medical School, Worcester, Massachusetts, and colleagues.
GLP-1 receptor agonists may reduce appetite and food intake, raising concerns about adequate protein consumption, particularly among older adults at risk of age-related muscle loss.
Researchers analysed nationally representative NHANES data from 2017 to March 2020, including adults aged 20 years and older with pharmacologically treated T2D. GLP-1 RA use was identified through medication inventories, while dietary intake was assessed using two nonconsecutive 24-hour recalls.
Protein intake was compared against age-specific recommendations: 0.8 g/kg/day for adults aged 20–64 years and 1.0–1.2 g/kg/day for those aged 65 years and older.
The analysis included 673 adults, comprising 38 GLP-1 RA users and 635 non-users, representing approximately 18.4 million US adults. The findings revealed:
  • Adults aged 20–64 years (358 participants) reported a mean protein intake of 0.89 g/kg/day, above the RDA of 0.8 g/kg/day.
  • Among 315 adults aged 65 years and older, mean protein intake was 0.87 g/kg/day, falling below the recommended range of 1.0–1.2 g/kg/day.
  • GLP-1 RA users reported lower mean protein intake than nonusers (0.74 vs. 0.89 g/kg/day), although adjusted dietary comparisons were imprecise.
  • GLP-1 RA users had a higher mean body mass index (BMI) than nonusers (37.6 vs. 32.8 kg/m²).
  • The adjusted difference in energy intake was −373.7 kcal/day, with the analysis unable to establish clear dietary differences between medication users and nonusers.
The findings highlight the need for individualized nutritional assessment in adults with T2D, particularly older adults and GLP-1 RA users. Protein requirements should be assessed considering age, body weight, renal function and clinical status. However, the study did not establish protein deficiency, muscle loss or adverse nutritional outcomes.
The cross-sectional design, small number of GLP-1 RA users and imprecise adjusted comparisons limit interpretation. The findings do not establish that GLP-1 RAs cause changes in dietary intake or nutritional inadequacy.
Reference:
Harvey, J. T., Baek, J., Caouette, J. L., & Lapane, K. L. (2026). Dietary Protein Intake Relative to Adult and Older-Adult Reference Intakes in Type 2 Diabetes, by Use of Glucagon-Like Peptide-1 Receptor Agonists: A Nationally Representative Cross-Sectional Study. Obesity Pillars, 100354. https://doi.org/10.1016/j.obpill.2026.100354


Tags:    
Article Source : Obesity Pillars

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .